PRMT5 and urinary bladder neoplasm: To confirm the essential role of PRMT5 as a therapeutic target in vitro, we investigated the effect of EPZ015666, a selective PRMT5 inhibitor (Braun et al., 2017[4]; Chan-Penebre et al., 2015[5]), on bladder tumor growth.